Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Cardiology/Vascular Diseases | Hematology
Clinical Trials: Vascular Diseases
A listing of clinical trials currently looking for volunteers to enroll in Vascular Diseases studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University Of Alabama
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Huntsville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Mobile : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Arizona
Cottonwood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Glendale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Tucson :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Arkansas
California
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Fair Oaks : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Fremont : Mission Cardiovascular Research Institute
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Lomita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Mission Viejo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
San Francisco : Kaiser Permanente
TX2® Low Profile TAA Endovascular Graft
San Jose : VIVA Physicians Inc.
Study to Evaluate the Safety and Performance of the Xpert(TM) Stent in Treating Below-the-Knee Lesions in Patients Undergoing Percutaneous Intervention for Chronic Critical Limb Ischemia
Santa Clara : Abbott Vascular
Absolute Pro® MOMENTUM™
Santa Clara : Abbott Vascular
EXCEL Clinical Trial
Santa Clara : Abbott Vascular
The ABSORB BTK (Below The Knee) Clinical Investigation
Santa Rosa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Stockton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Torrance : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Westlake Village : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Colorado
Connecticut
Delaware
Newark : Christiana Care
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
District of Columbia
Washington : Washington Hospital Center
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Washington : Washington Hospital Center
TX2® Low Profile TAA Endovascular Graft
Florida
Pembroke Pines : University Clinical Research, Inc.
Men and Women ages 18 or older with High Blood Pressure and Diabetes Type 2 who DO NOT require the use of Insulin to control their Diabetes Levels
View More »
Aventura : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Bradenton : Bradenton Cardiology Center
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Brandon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Clearwater : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Delray Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Fleming Island : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Gainesville : Florida Research Network
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
Inverness : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Jacksonville : First Coast Cardiovascular Institute
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Jacksonville : Baptist Health Medical Center
The Evicel Post-Authorization Surveillance Study
Jacksonville Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Jupiter : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Lakeland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Largo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Margate : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Melbourne : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Miami : University of Miami Sylvester Comprehensive Cancer Center
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Miami Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Miami Beach : Mount Sinai Miami Medical Center
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
Naples : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Ocala : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Panama City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Pembroke Pines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Pensacola : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Ponte Vedra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Port Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Safety Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Tallahassee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Wellington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Georgia
Illinois
Arlington Heights : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Aurora : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Elk Grove Village : Cardiovascular Associates
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Jerseyville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Rock Island : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Rockford : Rockford Cardiovascular Associates
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Indiana
Anderson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Brownsburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Elkhart : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Fort Wayne : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Hammond : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Indianapolis : Methodist Cardiology Physicians
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Indianapolis : Indiana Heart Hospital
TX2® Low Profile TAA Endovascular Graft
Munster : Cardiovascular Research of NW IN
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Iowa
Kansas
Kentucky
Louisiana
Baton Rouge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Covington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Lake Charles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Maine
Maryland
Baltimore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Lutherville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
North East : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Salisbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Takoma Park : Washington Adventist Hospital / Center for Cardiac & Vascular Research
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
Massachusetts
Haverhill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Hyannis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Natick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Michigan
Ann Arbor :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Ann Arbor : University of Michigan
TX2® Low Profile TAA Endovascular Graft
Cadillac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Lansing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Lansing : Thoracic Cardiovascular Institue
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
View More »
Lansing : Thoracic & Cardiovascular Healthcare Foundation
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
Marquette : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Midland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Novi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Petoskey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Pontiac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Saginaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Saginaw : Michigan CardioVascular Institute
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Wyoming : Metro Heart & Vascular
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Ypsilanti : Michigan Heart
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Minnesota
Mississippi
Jackson :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Tupelo : North Mississippi Medical Center
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Missouri
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Kansas City : Kansas City Heart Foundation/Kansas City Cardiology Associates
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
St. Louis : Barnes-Jewish Hospital
TX2® Low Profile TAA Endovascular Graft
Montana
Nebraska
New Hampshire
New Jersey
Bridgewater : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Camden : Cooper University Hospital
TX2® Low Profile TAA Endovascular Graft
Elizabeth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Elmer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Haddon Heights : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Mine Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Ridgewood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Ridgewood : Cardiac and Endovascular Associates
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Sewell : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Somerset : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Teaneck : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Toms River : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
Multicenter, Open-Label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) after a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects with Known or Suspected Vascular Disease of the Supra-Aortic Vessels
Manhasset : Biomedical Research Alliance of New York
Carotid Stenting and Angioplasty in patients at high-risk for endarterectomy
View More »
Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Bronx :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Bronx : Montefiore Medical Center
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Kingston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
New York : Columbia University Medical Center
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
New York : Novartis Investigative Site
Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease
New York : Columbia University Medical Center, Center for Interventional Vascular Therapy
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
New York : Mount Sinai Hospital
TX2® Low Profile TAA Endovascular Graft
New York : New York University Hospital
TX2® Low Profile TAA Endovascular Graft
Poughkeepsie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Rochester :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Roslyn : St. Francis Hospital
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
Saratoga Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Southampton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Stony Brook : Stony Brook University Medical Center
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
Troy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Westfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Williamsville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
North Carolina
Raleigh : Rex Healthcare
AMPLIFY- A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism
Raleigh : Wake Research Associates
Study of High LDL (Bad Cholesterol)
View More »
Asheville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Cary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Chapel Hill : University of North Carolina
TX2® Low Profile TAA Endovascular Graft
Durham : Duke University Medical Center
TX2® Low Profile TAA Endovascular Graft
Elizabeth City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Greensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Hickory : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Lenoir : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Wilmington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Ohio
Beachwood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Canton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Cincinnati : University of Cincinnati
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Cleveland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Cleveland : Cleveland Clinic Foundation
TX2® Low Profile TAA Endovascular Graft
Columbus : OhioHealth Research Institute
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
Columbus : The Ohio State University Medical Center
Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)
Columbus : Ohio State University
TX2® Low Profile TAA Endovascular Graft
Mansfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Sandusky : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Toledo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Toledo : Cardio Vascular Research UT Heart and Vascular Center
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Toledo : Jobst Vascular
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Zanesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Oklahoma
Oregon
Pennsylvania
Abington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Beaver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Camp Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Camp Hill : Spirit Physician Services / Capital Cardiovascular Associates / Holy Spirit Hospital
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
View More »
Danville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Doylestown : Central Bucks Specialists
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Doylestown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Doylestown : Central Bucks Specialists
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Greensburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Langhorne : St Mary Medical Center Research Institute
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Mechanicsburg : Capital Cardiovascular Associates
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Philadelphia :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Philadelphia : Hospital of the University of Pennsylvania
TX2® Low Profile TAA Endovascular Graft
Pittsburgh : University of Pittsburgh Medical Center
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Pittsburgh : Allegheny Singer Research Institute
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Port Matilda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Pottstown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Red Lion : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Wilkes-Barre : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Wormleysburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Rhode Island
South Carolina
Charleston : Medical University of South Carolina
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Columbia : South Carolina Heart Center
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Greenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Greer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Rock Hill : Carolina Cardiology Associates
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
South Dakota
Tennessee
Greeneville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Kingsport : Wellmont CVA Heart Institute
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Knoxville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Memphis :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Tullahoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Texas
Amarillo : Cardiology Center of Amarillo
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Austin : Texas Heart & Vascular/THV Research
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Corpus Christi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Houston : Memorial Hermann Hospital
Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease
View More »
Houston : Baylor College of Medicine
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
Kerrville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Kingwood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
McKinney : North Dallas Research Associates
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Tomball : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Waco : Providence Health Center
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Utah
Salt Lake City : Optimum Clinical Research, Inc.
Type 2 Diabetes and High Blood Pressure.
View More »
Bountiful : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Murray : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Virginia
Charlottesville : University of Virginia
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Danville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Falls Church : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Falls Church : Inova Fairfax Hospital
TX2® Low Profile TAA Endovascular Graft
Harrisonburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Lynchburg : Centra Cardiovascular Group
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Lynchburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Norfolk : Sentara Medical Group
A Multi-center Clinical Trial of the Misago(TM) Self-Expanding Stent System for Superficial Femoral Artery
Norfolk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Roanoke : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Washington
West Virginia
Wisconsin
Argentina
Belgrano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Córdoba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
San Luis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
San Miguel De Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Australia
Box Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Camperdown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Clayton :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Geelong : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Heidelberg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Herston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Milton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
New Lambton Heights :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Parkville :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Southport : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Windsor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Wollongong : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Austria
Graz : LKH/Uniklinikum - Klinische Abteilung für Kardiologie
Graz Study on the Risk of Atrial Fibrillation
Graz : Medical University of Graz
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Graz : Medical University
Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe
Innsbruck :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Wien :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Belgium
Bonheiden : Imelda Hospital / Flanders Medical Research Program
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
Bonheiden : Patrick Peeters, MD
Tack Optimized Balloon Angioplasty (TOBA) Study
Dendermonde : A.Z. Sint-Blasius Hospital / Flanders Medical Research Program
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
Dendmermonde : Az Sint-Blasius
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Bulgaria
Canada
Brossard : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Cambridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Gatineau : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Greenfield Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Kelowna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
London : Robarts Research Institute
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
Longueuil : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Mississauga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Montreal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Montreal : Centre Hospitalier de L' Universite de Montreal
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Mount Pearl : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Oshawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Sainte-Foy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Saint-Georges : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Sarnia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
St-Jerome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
St-Lambert : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Sudbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Thunder Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Toronto : University Health Network
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Toronto : University Heatlh Network, Toronto General Hopsital
Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol
Vancouver : University of British Columbia Gerontology & Diabetes Research Centre
The Effect of a Diabetes Action Team in Patients Post Infrainguinal Bypass Surgery With and Without Diabetes
Chile
Santiago : Pontificia Universidad Catolica de Chile
Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System
Czech Republic
Brno :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Hodonin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Marianske Lazne : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Pardubice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Pisek : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Prague : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Denmark
Aalborg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Ballerup : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Copenhagen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Kobenhavn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Vejle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Estonia
France
Angers : Laboratoire d'explorations vasculaires
Objective Evaluation of Proximal Ischemia
Avignon : Centre Hospitalier d'Avignon
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Besançon : CHU de Besancon, Hôpital Jean Minjoz
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Bordeaux : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Brest Cedex :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
View More »
BRON Cedex :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Challes-les-Eaux : Médipôle de Savoie
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Créteil : Groupe Hospitalier Henri-Mondor
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Dijon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Evry : Clinique du Mousseau
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Fleury les Aubrais : Clinique de la Présentation
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Le Coudray : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Marseille : Hôpital Paul Desbief
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Marseille : Hôpital Ambroise Paré
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Marseille :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Montfermeil : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Montpellier : Clinique du Millenaire
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Paris :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Pessac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Quimper : Polyclinique Quimper Sud
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Toulon : CHl Toulon - La Seyne sur Mer
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Toulouse : Clinique Sarrus Teinturiers
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Trélazé : Clinique Saint Joseph
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
Germany
Augsburg :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Bernau : Herzzentrum Brandenburg in Bernau
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease
Coburg : Klinikum Coburg GmbH
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease
Erlangen :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Essen : Elisabeth-Krankenhaus Essen GmbH
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease
View More »
Hamburg : Medical Care Center Prof. Mathey, Prof. Schofer GmbH
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease
Jena :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Karlsruhe :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Kiel : Universitätsklinikum Schleswig-Holstein
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease
Kiel : University Hospital of Kiel
The eSVS® Mesh Randomized Post-Market Study
Ulm : Universitätsklinikum Ulm
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease
Hungary
Bekescsaba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Debrecen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Esztergom : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Hodmezovasarhely : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Kalocsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Kistarcsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Komarom : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Oroshaza : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Szekszard : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Zalaegerszeg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
India
Ireland
Dublin 4 :
A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery
Israel
Ramat Gan : Sheba Medical Center
Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia
Italy
Aosta :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Bologna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Caserta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Catania :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Lagosanto :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
View More »
Massa :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Mestre :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Milano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Roma :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Japan
Chiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Ehime : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Gunma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Kyoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Okinawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Tokushima : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Korea, Republic of
Lithuania
Kaunas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Klaipeda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Vilnius : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Mexico
Aguascalientes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Chihuahua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Cul Sinaloa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Huixquilucan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Queretaro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
San Luis Potosi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Tampico : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Tijuana : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Netherlands
Nijmegen : Radboud University Nijmegen Medical Center
X-ray Dose Reduction Study for Cardiac Angiography and Intervention
Rotterdam :
A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery
New Zealand
Auckland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Christchurch : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Grafton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Tauranga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Wellington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Peru
Chorrilos : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Lima : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Lince : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Poland
Bydgoszcz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Bydgoszcz :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Gdansk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Katowice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Krakow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Lodz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Lodz :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Olawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Pulawy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Skierniewice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Sobotka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Warszawa :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Wroclaw :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Puerto Rico
Ponce : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Trujillo Alto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Slovakia
Bardejov : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Bratislava : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Kralovsky Chlmec : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Nitra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Presov : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Zilina : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
South Africa
Alberton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Bellville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Goodwood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Johannesburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Kuilsriver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Newlands West : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Worcester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Spain
Ciudad Real : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Cordoba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
L´Hospitalet De Llobregat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Málaga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
View More »
Palma De Mallorca : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Pamplona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Sant Boi De Llobregat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Sweden
Linköping :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Uppsala :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Switzerland
Basel : University Hospital
The eSVS® Mesh Post-Marketing Trial
Lausanne : Service de Chirurgie cardio-vasculaire CHUV
New Anastomotic Device for End to End Vascular Anastomosis in the Treatment of Peripheral Vascular Disease
Turkey
Ankara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Antalya : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Antalya :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Erzurum : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Erzurum :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
View More »
Istanbul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Istanbul :
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Kayseri : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Konya : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
United Kingdom
Barnet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Bath : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Dudley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Frome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Oxford : CTSU, University of Oxford
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
View More »
St. Stephen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Wellingborough : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
Welwyn Garden City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Evacetrapib in High-Risk Vascular Disease
